Sunesis And Chiesi Enter Drug Discovery Agreement

Sunesis Pharmaceuticals, Inc. and Chiesi Farmaceutici S.p.A have entered into a research collaboration to discover and develop small molecules that inhibit a well-validated protein-protein target involved in immunological diseases. Using its proprietary discovery technology, Sunesis will generate development candidates and Chiesi will have an exclusive option to enter into an exclusive license to develop and Read more about Sunesis And Chiesi Enter Drug Discovery Agreement[…]

Deltagen And Hyseq To Develop Novel Secreted Proteins

Deltagen, Inc., and Hyseq, Inc. have announced a major collaboration to undertake the research and development of approximately 200 novel secreted proteins. Under the terms of the agreement, Hyseq will provide gene sequences encoding secreted proteins from their extensive intellectual property portfolio and Deltagen will utilize its proprietary in vivo mammalian gene knockout technology to Read more about Deltagen And Hyseq To Develop Novel Secreted Proteins[…]

Ciphergen Enters Collaboration With Pfizer

Ciphergen Biosystems, Inc. has entered into a collaboration with Pfizer Inc. designed to discover proteins in serum from rat models as well as to evaluate the relative importance and utility of such proteins as biomarkers associated with drug safety. “This innovative predictive toxicology study will be carried out through our Biomarker Centers,” commented William Rich, Read more about Ciphergen Enters Collaboration With Pfizer[…]

Tranzyme And Active Pass Announce Collaboration

Tranzyme, Inc. and Active Pass Pharmaceuticals, Inc. have entered into a collaboration in the areas of gene expression and drug discovery. This alliance will utilize Tranzyme’s TExT (Tranz Expression Technology) in support of the ABC Transporter chemogenomic program at Active Pass. Under this collaboration, Active Pass will provide multiple sets of ABC transporter gene sequences, Read more about Tranzyme And Active Pass Announce Collaboration[…]

LSBC And Phylogix Form Bioprocessing Alliance

Phylogix, Inc. and Large Scale Biology Corporation have formed a bioprocessing alliance to develop and manufacture Phylogix, Inc.’s lead therapeutic protein, a native protein in hyacinth seeds called FRIL. The protein represents a novel chemoprotective agent that, in animals, has demonstrated a unique ability to protect normal tissues from the toxic side effects of chemotherapy. Read more about LSBC And Phylogix Form Bioprocessing Alliance[…]

Cerylid, Anadys Sign Anti-infective Collaboration

Cerylid Biosciences Limited and Anadys Pharmaceuticals, Inc. have announced a strategic partnership for the discovery of novel anti-infective compounds. This partnership will utilize Anadys’ uHTS-ATLAS technology to screen Cerylid’s world leading collection of natural products against key Anadys targets. Under the terms of the collaboration, Anadys will gain access to Cerylid’s extensive library of unique Read more about Cerylid, Anadys Sign Anti-infective Collaboration[…]

Virologic Expands Pact With Pfizer

ViroLogic Inc. has signed an expanded agreement with Pfizer Inc. to use ViroLogic’s HIV resistance testing technology for Pfizer’s HIV drug discovery and development programs.ViroLogic said the new pact covers work performed for all of Pfizer’s global research and development sites worldwide. As recommended by the FDA’s antiviral drugs advisory committee, biopharmaceutical companies are using Read more about Virologic Expands Pact With Pfizer[…]

Centocor Expands Cancer Vaccine Agreement

Centocor, Inc., a Johnson & Johnson company, has expanded its earlier license and option agreement to use Vical‘s Incorporated naked DNA technology to develop and commercialize certain DNA vaccines for the potential treatment of some types of cancer. Vical will receive an undisclosed upfront payment and could receive additional milestone payments in the future. The Read more about Centocor Expands Cancer Vaccine Agreement[…]

Isis, Lilly Expand Collaboration Into Cancer Drugs

Isis Pharmaceuticals Inc. and Eli Lilly and Co. have expanded their collaboration to develop cancer drugs based on a technology known as antisense. Isis, a small biotechnology company based in Carlsbad, California, and drug giant Lilly, based in Indianapolis, said they had formed a two-year collaboration to discover drugs associated with specific genes that the Read more about Isis, Lilly Expand Collaboration Into Cancer Drugs[…]

GeneFormatics Inc. And Arakis Agree Drug Discovery Collaboration

GeneFormatics Inc. and Arakis Limited have announced a collaborative agreement for the joint discovery of Performance Enhanced Medicines (PEMs). PEMs are novel pharmaceutical products created using advances in biology to identify applications of established drugs in new indications. Additional clinical and patient benefit is provided using a diverse range of pharmaceutical technologies primarily drug delivery Read more about GeneFormatics Inc. And Arakis Agree Drug Discovery Collaboration[…]